Agouron Pharmaceuticals, Inc.

Tracon Pharmaceuticals, Inc.

Suzanne Pritchett Benedict

Min Teng

Sacha Ninkovic

Michael John Bennett

Yong Wang

Fen Wang

Jinjiang Zhu

Eugene Yuanjin Rui

Brian P Murphy

Mark Cornell Manning

Sepehr Sarshar

Steven Lee Bender

Allen Borchardt

Mitchell David Nambu

Dilip Ramakant Bhumralkar

Charles P Theuer

Anna Maria Tempczyk-Russell

Shao Song Chu

Yuanjin Rui

Larry Andrew Alegria

Zhengwei Peng

Sharon Real

Michelle Yang

Robert Steve Kania

The present application relates to formulations of anti-CD105 antibodies, antigen-binding fragments thereof, and uses thereof. Another aspect relates to pre-filled syringes of the formulations of anti-CD105 antibodies or antigen-binding fragments thereof. Another aspect relates to the use of the formulations to reduce one or more signs or symptoms of an angiogenesis-related disorder such as cancers and ophthalmologic diseases.

Antibody formulations and uses thereof

Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R, Rand Rare as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers. The current invention relates to the making and using of such compounds.

Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy

Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R, Rand Rare as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.

Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R, Rand Rare as defined in the specification)pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.

Diaminothiazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use

Growing community of inventors

San Diego, CA, United States of America

Suzanne Pritchett Benedict